The first gene therapy, voretigene neparvovec‐rzyl (Luxturna®, Spark Therapeutics, Inc., Philadelphia, USA), for inherited retinal degenerations received marketing approval from the US Food and Drug Administration in 2017 for the treatment of biallelic retinoid isomerohydrolase RPE65 (RPE65) mutation causing Leber congenital amaurosis and RP [6]. Here, RPE65 is linked to Leber congenital amaurosis.